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A public health approach for deciding policy on infant 
feeding and mother–infant contact in the context of 
COVID-19
Nigel Rollins, Nicole Minckas, Fyezah Jehan, Rakesh Lodha, Daniel Raiten, Claire Thorne, Philippe Van de Perre, Mija Ververs, Neff Walker, 
Rajiv Bahl, Cesar G Victora, on behalf of the WHO COVID-19 Maternal, Newborn, Child and Adolescent Health Research Network, Newborn and 
Infant Feeding Working Groups
The COVID-19 pandemic has raised concern about the possibility and effects of mother–infant transmission of 
SARS-CoV-2 through breastfeeding and close contact. The insufficient available evidence has resulted in differing 
recommendations by health professional associations and national health authorities. We present an approach for 
deciding public health policy on infant feeding and mother–infant contact in the context of COVID-19, or for future 
emerging viruses, that balances the risks that are associated with viral infection against child survival, lifelong health, 
and development, and also maternal health. Using the Lives Saved Tool, we used available data to show how different 
public health approaches might affect infant mortality. Based on existing evidence, including population and survival 
estimates, the number of infant deaths in low-income and middle-income countries due to COVID-19 (2020–21) 
might range between 1800 and 2800. By contrast, if mothers with confirmed SARS-CoV-2 infection are recommended 
to separate from their newborn babies and avoid or stop breastfeeding, additional deaths among infants would range 
between 188 000 and 273 000.
Introduction
Exclusive and continued breastfeeding, skin-to-skin 
contact initiated in the first hour of birth, and responsive 
caregiving are strongly recommended by WHO for 
all infants and young children. Kangaroo mother care is 
also strongly recommended for all low-birthweight 
newborn babies.1 High-quality evidence has shown 
the benefits of these interventions on child survival, 
health, and development. The COVID-19 pandemic, 
caused by SARS-CoV-2 has, however, raised concern 
about the possibility and effect of SARS-CoV-2 
transmission through close contact between mothers 
and their infants and breastfeeding. As of Aug 14, 2020, 
analyses of breastmilk samples of 175 mothers with 
confirmed SARS-CoV-2 infection have been reported,2 
with SARS-CoV-2 RNA identified by RT-PCR in samples 
from ten mothers. However, evidence of infectious virus 
that is capable of replicating and infecting other cells3 
and mother–infant transmission through breastmilk 
has not been shown.
Interpretation of existing evidence and how it 
should shape public health policy is challenging because 
the population effects and long-term health outcomes 
of COVID-19 among mothers and infants are 
uncertain. WHO interim guidance4 (May 27, 2020), on 
the basis of available evidence, recommends that 
“mothers with suspected or confirmed COVID-19 should 
be encouraged to initiate and continue breastfeeding”, 
while implementing infection control measures, and 
“should not be separated from their infants unless the 
mother is too sick to care for her baby”. The guidance 
notes that the severity of COVID-19 infections is 
much lower in infants than in adults and that “COVID-19 
in infants and children represents a much lower 
risk to survival and health than the other infections 
and conditions that breastfeeding is protective against”. 
Some national health agencies, however, have advised 
separation of infants from mothers with suspected 
or confirmed SARS-CoV-2 and avoidance of breast-
feeding5,6—although some have revised their position. A 
Cochrane review of 19 national policies reported no 
consensus regarding whether breastfeeding should be 
contraindicated among mothers with confirmed or 
suspected COVID-19 and even among asymptomatic 
mothers with unknown COVID-19 status.7 Reports of 
SARS-CoV-2 RNA in breastmilk, even without evidence 
of transmission, have fuelled uncertainty and anxiety 
and even led some authors to recommend against 
breastfeeding.8 Unsurprisingly, health workers and 
communities are confused about appropriate infant 
feeding recommendations.9 In some settings, local 
policies to prevent COVID-19 have resulted in delays in 
initiation of and disruption in breastfeeding among 
mothers with unknown COVID-19 status.9 Furthermore, 
the pandemic and related evidence gaps and anxieties are 
egregiously being exploited as a marketing opportunity 
by the breastmilk substitute industry.10,11
An approach for deciding public health policy
Even in the absence of high-quality data, public health 
policy should, to the extent possible, be evidence-based. 
We present an approach based on available evidence for 
the competing benefits and harms (panel) for developing 
policy on mother–infant contact and infant feeding 
practices in the context of COVID-19, or for other viral 
agents that might appear in the future, that balances 
the risks associated with viral infection with the effect 
on child survival, lifelong health, and development. 
Considerations include the incidence among mothers, 
duration of infectivity, feasibility of identifying infection 
Lancet Glob Health 2021; 
9: e552–57
Published Online 
February 22, 2021 
https://doi.org/10.1016/
S2214-109X(20)30538-6
Department of Maternal, 
Newborn, Child and Adolescent 
Health and Ageing, World 
Health Organization, Geneva, 
Switzerland (N Rollins MD, 
N Minckas MSc, R Bahl PhD); 
Department of Pediatrics and 
Child Health, Aga Khan 
University, Karachi, Pakistan 
(F Jehan MSc); Department of 
Pediatrics, All India Institute of 
Medical Sciences, New Delhi, 
India (R Lodha MD); 
Eunice Kennedy Shriver 
National Institute of Child 
Health and Human 
Development, National 
Institutes of Health, Bethesda, 
MD, USA (D Raiten PhD); UCL 
Great Ormond Street Institute 
of Child Health, University 
College London, London, UK 
(C Thorne PhD); Pathogenesis 
and Control of Chronic 
Infections, INSERM, 
Etablissement Français du 
Sang, University of 
Montpellier, CHU Montpellier, 
Montpellier, France 
(P Van de Perre MD); Johns 
Hopkins Bloomberg School of 
Public Health, Baltimore, MD, 
USA (M Ververs MSc, 
N Walker PhD); International 
Center for Equity in Health, 
Federal University of Pelotas, 
Pelotas, Brazil (C G Victora MD)
Correspondence to: 
Dr Nigel Rollins, Department of 
Maternal, Newborn, Child and 
Adolescent Health and Ageing, 
World Health Organization, 
CH-1211 Geneva 27, Switzerland 
rollinsn@who.int
Health Policy
e553 www.thelancet.com/lancetgh   Vol 9   April 2021
in a timely manner, SARS-CoV-2 transmission risks, and 
effects of infection in infants, alongside the mortality 
and health risks of separation and not breastfeeding. In 
time, relevant data will become available and should be 
interpreted while recognising complementary effects of 
these considerations and dependent outcomes. Here, we 
consider the risk of exposure to SARS-CoV-2 that is 
associated with close contact and breastfeeding and 
compare this risk with the risks of no contact between 
the mother and infant and avoidance or stopping of 
breastfeeding (and use of breastmilk substitute).
Policy considerations for mothers with confirmed 
SARS-CoV-2
On consideration of a balance of risk, public health 
policy would favour separation and avoiding breast-
feeding among mothers with confirmed SARS-CoV-2 if 
evidence exists of substantial, immediate or potential 
long-term adverse health effects of COVID-19 in infants 
or young children; of substantive SARS-CoV-2 trans-
mission through mother–infant contact or breastfeeding; 
and identification of mothers with SARS-CoV-2 while 
infectious, with or without symptoms. These conditions 
Panel: Available evidence and key research and programme gaps
SARS-CoV-2 infection fatality rate
Available evidence
• Preliminary data from south Asia and Latin America indicate 
very low infection fatality rates in infants and young children 
(appendix p 7)
Research and programme gaps
• What is the infection fatality rate of severe acute 
respiratory syndrome coronavirus 2 (SARS-CoV-2) in 
infants and young children by age, nutritional status, 
comorbidity, socio-economic setting and health system 
capacity?
Mortality and long-term health outcomes of mother–infant 
contact and breastfeeding
Available evidence
• High quality data show survival and long-term health 
benefits that are associated with early initiation of and 
exclusive and continued breastfeeding (cumulative benefits 
with longer durations of breastfeeding) and with mother–
infant contact (appendix p 7)
• Breastfeeding rates decrease when health-care workers 
communicate mixed messages (appendix p 7)
• Breastfeeding rates decrease as a result of marketing of 
breastmilk substitutes (appendix p 7)
Research and programme gaps
• What are the protective effects of specific anti-SARS-CoV-2 
factors in breastmilk?
SARS-CoV-2 transmission risk through mother–infant 
contact and breastfeeding
Available evidence
• SARS-CoV-2 RNA identified intermittently in breastmilk
• Evidence for transmission competent virus not reported in 
breastmilk (appendix pp 7–8)
• No transmission through breastfeeding reported
• COVID-19 neonatal deaths mostly among preterm babies 
and when the mother is seriously unwell (and therefore 
separated; appendix pp 7–8) 
• SARS-CoV-2 antibodies identified in breastmilk (appendix 
pp 7–8)
• Lactoferrin and many other anti-infectious molecules 
(eg, secretory leucocyte protease inhibitor and lysozymes) 
present in breastmilk with potential anti-SARS-CoV-2 
activity (appendix pp 7–8)
Research and programme gaps
• Is active transmission-competent virus present in 
breastmilk?
• If present, how frequently, for how long, and what is the 
relationship to symptoms (before and after symptoms)?
• What is the transmission rate through respiratory droplets 
and close contact by infant age and time in contact with 
mother when asymptomatic or infectious?
• What is the additional transmission rate through breastfeeding 
by infant age and amount of breastmilk consumed?
• What is the ability of virus to overcome host defences 
according to infant age?
Identification of mothers with confirmed SARS-CoV-2 
infection
Available evidence
• Testing done only once symptoms present or during a 
contact tracing process (eg, when a relative or other 
household member has symptoms or tests positive for 
infection; appendix p 8)
• Some centres doing tests in all mothers who present in 
labour (appendix p 8)
• Time to return of results 24–72 h or longer, although some 
accredited tests provide PCR result within 60 min (GenXpert 
and others; appendix p 8)
• Testing not available in many facilities, including 
high-resource settings (appendix p 8)
• 5–20% of individuals with suspected COVID-19 are likely to 
test positive for SARS-CoV-2;12 in other reports, 52–96% of 
individuals who were tested because of symptoms 
suggestive of COVID-19 were negative and had a different 
cause of symptoms (appendix p 8)
Research and programme gaps
• What is the transmission risk associated with mother–infant 
contact and other caregivers and household members while 
the mother is asymptomatic or with early symptoms 
(pre-results)?
• What are the best approaches for rapid testing?
See Online for appendix
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are all necessary if avoidance of contact and breastfeeding 
are to produce an overall benefit.
Conversely, public health policy for mothers with 
confirmed SARS-CoV-2 infection would favour continued 
breastfeeding and mother–infant contact if evidence 
exists for substantial risk of immediate infant or child 
death or long-term adverse effects associated with 
separation and non-breastfeeding for the infant or 
mother; few negative health effects of COVID-19 among 
infants or young children; and low risk of SARS-CoV-2 
transmission through mother–infant contact and 
breastfeeding.
Mother–infant contact and breastfeeding are normative 
recommendations and therefore standard of care. If any 
of the inputs that justify separation and non-breastfeeding 
are absent, then the chain of effects supporting a policy 
that is different from standard care would be broken. For 
mothers with suspected COVID-19 but who have not 
been tested or confirmed, justification for a policy in 
favour of separation and avoiding breastfeeding would 
need evidence of a high likelihood of SARS-CoV-2 
infection in those with suspected infection and even 
greater harm associated with COVID-19 to allow for false 
positives. A policy that is in favour of separation and non-
breastfeeding should also address the potential for 
altered feeding practices in the general population—ie, 
diminished breastfeeding because of public health mixed 
messaging and confusion among health workers and 
beliefs based on risk aversion.
COVID-19 chain of risks and effects of policy 
options: illustrative analyses
Here, we consider the effects of inputs that sequentially 
and cumulatively influence the balance of risks for 
infants living in low-income and middle-income 
countries (LMICs). We estimated the effects of separation 
and non-breastfeeding by mothers with confirmed 
SARS-CoV-2 (with or without symptoms), identified 
either through universal testing of mothers of newborn 
babies or through testing of mothers presenting with 
COVID-19 symptoms. We estimated the potential 
number of infant deaths in 119 LMICs (appendix pp 4–6) 
that annually might be attributable to COVID-19 as well 
as the additional deaths due to separation and non-
breastfeeding among infants who might be affected by 
such a policy approach. We also present data that are 
specific for 14 countries that show regional differences 
in neonatal and child mortality. We assumed a SARS-
CoV-2 incidence rate among mothers of 10%, although 
this figure is based on reported prevalence.13,14 In the 
absence of reported incidence data, this figure therefore 
overestimates actual incidence rates. SARS-CoV-2 
transmission rates through close contact between a 
mother who is infected but pre-symptomatic or 
persistently asymptomatic and her infant are unknown. 
A systematic review15 of 40 studies reported a mean 
overall household secondary attack rate of 18·8% 
(95% CI 15·4–22·2; median 16·3% [IQR 10·5–24·0]). 
Rates were higher from symptomatic than from 
asymptomatic index cases, and lower to child contacts 
than to adult contacts. The highest reported household 
secondary attack rate was 44·6%.16 SARS-CoV-2 RNA 
has been detected intermittently in breastmilk, but 
replication-competent virus that is capable of infecting 
other cells and presumably able to cause transmission 
has not been reported.3 For these estimates, we examined 
the effect of transmission probabilities of 20% and 30%. 
SARS-CoV-2 infection fatality rates (IFRs) among infants 
identified through universal screening of mothers are 
also unknown. We, therefore, used case fatality rates 
(CFRs) derived from infants and children who were 
symptomatic for COVID-19, tested, and received medical 
care. In a review of 7780 children in 26 countries with 
confirmed COVID-19, the CFR was 0·09%.17 Using CFR 
instead of IFR will therefore overestimate the number of 
deaths potentially attributable to SARS-CoV-2 infection.
We used the Lives Saved Tool (LiST) and current 
national mortality rates to estimate infant deaths in 
2020–21 that were attributable to separation and non-
breastfeeding among approximately 104 000 000 livebirths 
in 119 LMICs. LiST is a modelling tool for estimating 
direct and indirect effects of changes in coverage of 
health interventions, including skin-to-skin contact; 
exclusive, partial, and predominant breastfeeding in 
infants younger than 6 months; and any breastfeeding 
from age 6 months to 23 months on infant and child 
mortality (appendix pp 2–3).18 High-income countries 
were not included. Breastfeeding prevalence rates in 
LiST are based on country-specific data and are organised 
by four age groups: 0–<1 month, 1–5 months, 
6–11 months, and 12–24 months. The effect sizes of 
breastfeeding on survival vary by time of initiation, age, 
and category (ie, exclusive, predominant, or partial).19,20 
We examined two scenarios among infants of mothers 
with SARS-CoV-2 infection that was identified 
immediately after birth—eg, in the context of universal 
screening of mothers and also infants of mothers 
identified through testing if symptomatic in the first 
12 months after birth.
The first scenario was no initiation of breastfeeding 
among exposed newborn babies and older infants 
stopping breastfeeding, and no neonates or older 
infants subsequently restarting breastfeeding after the 
mother is no longer infectious—eg, if the mother 
received no counselling or other support to help restart 
breastfeeding. The second scenario involved early 
initiation of breastfeeding among all newborn babies; 
exposed newborn babies and older infants stopping 
breastfeeding; 50% of neonates and older infants 
restarting breastfeeding after mothers are no longer 
infectious (eg, the mother receives good counselling 
support and is able to restart breastfeeding); and 
considering the effects of non-breastfeeding projected 
through the first 12 months of life. 
For more on LiST see 
https://www.livessavedtool.org
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Infant mortality attributable to COVID-19 or a policy of 
separation and non-breastfeeding among mothers with 
confirmed SARS-CoV-2 infection
Based on existing evidence and the assumptions already 
described, annual deaths potentially attributable to 
COVID-19 in infants younger than 12 months in LMICs 
would be approximately 1875 or 2809 globally depending 
on whether the transmission probability is assumed to 
be 20% or 30%. Estimated deaths in infants aged 
0–12 months who might be affected by a policy of 
separation and non-breastfeeding among mothers with 
confirmed SARS-CoV-2 infection are presented in the 
table. Deaths among infants affected by a policy of 
separation and non-breastfeeding would be at least 
67 times greater than mortality potentially attributable 
to COVID-19 (table). Assuming 30% transmission, 
one would need to avoid mother–infant contact and 
breastfeeding among 3700 infants to prevent one COVID-
19-attributable death—ie, the number of newborn babies 
and infants who might be exposed to a policy requiring 
separation and non-breastfeeding in the event of maternal 
SARS-CoV-2 infection divided by the number of 
COVID-19 attributable deaths (table).
Discussion
Even assuming high rates of mother–infant SARS-CoV-2 
transmission through contact and breastmilk and using 
CFR instead of IFR, the additional deaths among 
newborn babies and infants in LMICs who would be 
subjected to separation and non-breastfeeding in either 
scenario (188 000 or 273 000) would be approximately 
67 times greater than the number of newborn babies and 
infants who are likely to die because of COVID-19. 
Because we assume higher incidence, transmission, and 
mortality associated with COVID-19 among newborn 
babies and infants than has been reported to date, this 
estimate is almost certainly an underestimate of the effect 
on mortality of a policy that would separate mothers from 
their newborn babies and disrupt breastfeeding. A low, or 
even very low, CFR in SARS-CoV-2-infected infants and 
children is the primary influence on this estimate, 
although lower transmission risks among infants and 
children, as suggested by existing evidence, are also 
important. An observational study21 that included 
116 mothers with confirmed SARS-CoV-2 reported no 
transmission among their newborn babies aged up to 
1 month, despite rooming in, and 78% practising breast-
feeding. Mothers also practised simple precautionary 
measures including wearing masks and hand hygiene.21 
Although high-income countries are not included in 
LiST, the benefits of exclusive and continued breastfeeding 
and use of breastmilk—eg, for infants with necrotising 
enterocolitis and for reducing hospital admissions for 
infectious diseases—are also likely to greatly outweigh 
the risks of COVID-19 in infants and young children. The 
presence of SARS-CoV-2 RNA in breastmilk in the 
absence of other evidence indicating that the virus can be 
transmitted through breastmilk is an important 
observation, but public health decisions that are based on 
this finding alone are not justified.
The analyses only consider the immediate mortality 
consequences of the two public health approaches. Yet, 
the adverse effects of delays and interruptions of 
breastfeeding might extend beyond any period of 
transient cessation related to the risk for SARS-CoV-2 
infection. Unless skilled breastfeeding counselling and 
support is available to individual mothers to help 
re-establish breastfeeding, temporary cessation is likely to 
diminish rates and duration of continued breastfeeding. 
Routine services have been disrupted by the pandemic in 
most settings and coverage of breastfeeding counselling 
is very likely to have also been affected.
Changes in feeding and care practice among mothers 
who are only suspected to have COVID-19, or by mothers 
of unknown status who are anxious or confused by the 
lack of accurate health messaging or through opportunistic 
marketing by the breastmilk substitute industry, will also 
indirectly increase mortality and losses in health status. If 
the non-survival benefits of breastfeeding for the child 
and mother22 are also considered, then much higher 
COVID-19 IFRs and transmission rates would be needed 
to justify a policy of separation and non-breastfeeding. 
Furthermore, separation of the infant from a mother with 














Additional infant* deaths 
because of early separation 
and no breastfeeding 
among exposed newborns 
and infants
Scenario 1 Scenario 2
Ghana 864 720 23·95 16 23 1983 1311
Nigeria 7 197 225 36·02 130 194 49 518 35 117
South Africa 1 204 852 10·74 22 33 1300 827
Argentina 747 792 6·36 13 20 123 75
Guatemala 425 986 12·30 8 12 685 509
Mexico 2 229 502 7·51 40 60 615 367
Lebanon 116 540 4·32 2 3 16 11
Pakistan 5 798 236 41·95 104 157 18 403 12 208
Turkey 1 320 135 5·46 24 36 182 118
Indonesia 4 749 802 12·74 85 128 5809 4015
Papua New 
Guinea
234 195 22·11 4 6 666 461
Thailand 709 759 5·02 13 19 95 62
India 23 724 430 22·73 427 641 46 937 31 928
Myanmar 942 842 36·74 17 25 2777 1926
Sri Lanka 326 879 4·49 6 9 49 34
All LMICs 
(119 countries)
104 051 261 17·67 1875 2809 273 453 188 626
CFR=case fatality rate. LMIC=low-income and middle-income countries. Data are n. *Age 0–12 months. †Assuming 
20% transmission rate and a CFR of 0·09%. ‡Assuming no separation and continued breastfeeding. §Assuming 
30% transmission rate and a CFR of 0·09%. 
Table: Estimated additional infant deaths (2020–21)
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remove all transmission risks for the infant. Transmission 
might also occur from exposure to infected but asympto-
matic carers at home, in health facilities, or in the 
community. In Brazilian national surveys, 13 (35%) of 
37 family members of participants who tested positive for 
SARS-CoV-2 antibodies also tested positive,23 inferring 
that to effectively implement a policy of separation, infants 
would have to be removed from their homes, which is 
clearly unrealistic.
The absence of accurate risk data presents a challenge 
for making public health recommendations. Empirical 
data will, in time, inform where the thresholds between 
low and high risks fall. While CFRs among infants and 
children presenting to health facilities are becoming 
available, IFRs, in which asymptomatic individuals and 
cases of mild illness also contribute to the denominator, 
are unknown and are perhaps not being investigated 
in population surveys. Also, adverse outcomes in 
young infants appear to have occurred principally among 
neonates who were born preterm or whose mothers had 
moderate-to-severe symptoms of COVID-19, making it 
difficult to ascertain what is attributable to COVID-19 
alone. In-utero transmission seems likely24 and might 
also bias postnatal outcome data, further complicating 
the interpretation of contact and infant feeding data 
in neonates. The protective effects of breastmilk against 
transmission of SARS-CoV-2 and the potential to mitigate 
infection through specific antibodies and anti-infectious 
agents in breastmilk are yet to be understood. However, 
components of breastmilk such as IgA, lactoferrin, and 
other anti-infectious molecules (eg, secretory leucocyte 
protease inhibitor and lysozymes) are likely to provide 
broad protection against viral invasion.
The COVID-19 pandemic shows how evidence with 
respect to infant feeding and care practices can be 
inconsistently assessed. The lack of consensus in 
recommendations and public health messaging 
suggests that risk aversion to the possible effects of 
COVID-19 have outweighed consideration of the 
survival and health benefits that skin-to-skin contact 
and breastfeeding offer to newborn babies and young 
infants. These mixed messages and concerns echo some 
of the perspectives and disagreement that occurred 
during the HIV epidemic when, in some settings, 
avoidance of postnatal trans mission was prioritised at 
almost any cost. Yet the transmission risks and 
consequences of COVID-19 are very different from 
those of HIV.25 The COVID-19 pandemic shows how 
approaches to policy making, whether in the context of 
COVID-19 or other infectious diseases, need to consider 
the full balance of risks, including the consequences of 
interrupting evidence-based infant-feeding practices 
and other standards of care.
Conclusions
On the basis of available evidence, including 
programmatic information and illustrative analyses, 
we make five conclusions. First, the state of evidence and 
balance of risk estimates support mother–infant close 
contact and breastfeeding by mothers with confirmed 
SARS-CoV-2 infection while still implementing infection 
prevention and control measures, including hand-
washing and wearing face masks.4 The survival benefits 
of breastfeeding substantially outweigh the very low 
reported CFRs among infants with COVID-19.4 Second, 
public health authorities should consider the full 
scope of evidence and implications for all-cause child 
mortality and other health outcomes, and ensure that 
resultant policy and associated messaging are coherently 
communicated to health-care workers and communities. 
Third, research will populate the evidence gaps and 
future estimations should adopt a compre hensive child 
survival and health framing to avoid oversimplification. 
Animal models would be helpful for elucidating 
infectivity of viruses through breastfeeding. Fourth, in 
the COVID-19 pandemic, breastfeeding counselling and 
support and other interventions and approaches should 
focus on how to reduce the small risk of transmission 
and effect through respiratory spread. Fifth, public health 
authorities and legislators should proactively address the 
deliberate exploitation and seeding of doubt about 
breastfeeding by commercial interests.
Future epidemics caused by novel viruses will 
probably involve similar challenges. The approach that 
we have presented will be useful for planning concerted 
advice that is globally consistent on risks and benefits 
associated with breastfeeding in light of potential viral 
transmission.
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